ondasdechoque.org
PT-BR

Achilles tendinopathy: mixed or unspecified location · Review · 2026

Does shockwave help long-lasting Achilles pain more than sham treatment?

In this review of 8 trials with 458 adults, pain and function with shockwave ended close to sham at 1, 3 and 6 months. People who had symptoms for less than a year may have had a little more early pain relief; that finding needs confirming.

Similar to sham overall
randomised trials
8
adults with long-lasting Achilles pain
458
compared with
Placebo

Good to know: Trials used radial or focused shockwave, mostly 3 to 4 sessions.

Ni T, Zhao Y, Pang L, et al. PeerJ, 2026 · Read the paper ↗

How this study worked

6 studies348 peopleOne answer
A review gathers earlier studies to answer one question.

Conceptual animation: a focused front converges, then spreads. Not to scale. Tap the field to send a pulse.

What happened

trials with 1-month pain results
6
people
348
Compared with
Sham shockwave; in most trials both groups also had the same exercise or advice

Pain: shockwave compared with sham

Difference in pain change, 0–10 scale

Across 6 trials at each time, pain with shockwave ended within about half a point of sham on a 0–10 scale, at 1 and 3 months.
Show the numbers
Difference (points on a 0–10 pain scale)likely range
Pain at 1 month−0.39−0.85 to 0.08
Pain at 3 months−0.56−1.4 to 0.28

What the trials used

ESWT modalities and dose range
Four studies radial, three focused, one combined; reported protocols used about 1,500–4,500 shocks/session over mostly three to four sessions. Intensities ranged 0.1–0.6 mJ/mm² or 1.5–5 bar as source-reported; do not convert between units.
Sham and co-interventions
Sham methods included zero energy, disconnected probes, air cavities or interposed material to attenuate waves while reproducing device cues. Seven studies matched exercise, stretching or education across arms; protocols varied.

Who took part

Eight RCTs included 458 adults with chronic Achilles tendinopathy. Outcome-specific pooled samples differed by endpoint/time; the source reports these in Table 4, with some malformed patient/study count cells for AOFAS.

Side effects

Mild side effects in 7 of 156 people with shockwave and 2 of 162 with sham; none needed treatment.

All the numbers and the full appraisal

Every reported result

FROM THE FULL PAPER

The results, in numbers.

Eight RCTs included 458 adults with chronic Achilles tendinopathy. Outcome-specific pooled samples differed by endpoint/time; the source reports these in Table 4, with some malformed patient/study count cells for AOFAS.

Pain change (ΔVAS)6 reported outcomes
01
1 month

Pain change (ΔVAS)

Visual Analog Scale (0–10) WMD points in change score

WMD-0.39CI 95% -0.85 to 0.08p = 0.10

ESWT versus sham ESWT

6 studies · 348 participants in this estimate · 0%

-1Equal results 00.2

Reported estimate and confidence interval.

No statistically significant pooled between-group difference was reported.

Analysis details and source

I²=0%; source-reported pooled change-score estimate.

02
3 months

Pain change (ΔVAS)

Visual Analog Scale (0–10) WMD points in change score

WMD-0.56CI 95% -1.4 to 0.28p = 0.19

ESWT versus sham ESWT

6 studies · 323 participants in this estimate · 64%

-1.6Equal results 00.5

Reported estimate and confidence interval.

No statistically significant pooled between-group difference was reported.

Analysis details and source

I²=64%; source-reported pooled change-score estimate.

03
6 months

Pain change (ΔVAS)

Visual Analog Scale (0–10) WMD points in change score

WMD0.14CI 95% -0.71 to 1p = 0.74

ESWT versus sham ESWT

2 studies · 127 participants in this estimate · 0%

-0.9Equal results 01.2

Reported estimate and confidence interval.

No statistically significant pooled between-group difference was reported.

Analysis details and source

I²=0%; source-reported pooled change-score estimate.

04
Over 6 months

Pain change (ΔVAS)

Visual Analog Scale (0–10) WMD points in change score

WMD-0.61CI 95% -1.78 to 0.56p = 0.31

ESWT versus sham ESWT

2 studies · 93 participants in this estimate · 0%

-2.1Equal results 00.8

Reported estimate and confidence interval.

No statistically significant pooled between-group difference was reported.

Analysis details and source

I²=0%; source-reported pooled change-score estimate.

11
1 month

Pain change with symptom duration <12 months, 1 month

Visual Analog Scale (0–10) WMD points in change score

WMD-0.76CI 95% -1.42 to -0.09p = 0.03

ESWT versus sham among participants with symptoms <12 months

4 studies · 173 participants in this estimate · 0%

-1.6Equal results 00.2

Reported estimate and confidence interval.

Exploratory subgroup difference favored ESWT but was smaller than the review-stated VAS MCID of 1.1 points; this hypothesis-generating result requires confirmation.

Analysis details and source

Prespecified symptom-duration subgroup per Methods, but explicitly treated as hypothesis-generating; do not generalize to the overall population.

12
3 months

Pain change with symptom duration <12 months, 3 months

Visual Analog Scale (0–10) WMD points in change score

WMD-1.23CI 95% -1.97 to -0.5p = 0.001

ESWT versus sham among participants with symptoms <12 months

3 studies · 119 participants in this estimate · 0%

-2.2Equal results 00.2

Reported estimate and confidence interval.

Exploratory subgroup difference favored ESWT and exceeded the review-stated VAS MCID of 1.1 points; this hypothesis-generating result requires confirmation.

Analysis details and source

Prespecified symptom-duration subgroup per Methods, but explicitly treated as hypothesis-generating; do not generalize to the overall population.

Function change (ΔVISA-A)3 reported outcomes
05
1 month

Function change (ΔVISA-A)

Victorian Institute of Sports Assessment–Achilles (VISA-A) WMD points in change score

WMD3.26CI 95% -0.98 to 7.49p = 0.13

ESWT versus sham ESWT

3 studies · 219 participants in this estimate · 72%

-2Equal results 08.5

Reported estimate and confidence interval.

No statistically significant pooled between-group difference was reported.

Analysis details and source

I²=72%; source-reported pooled change-score estimate. Values are as printed in Tables 4–6 (WMD 3.26, 95% CI −0.98 to 7.49, P = 0.13); the Results text reports WMD 2.79 (95% CI −5.27 to 10.86; I² = 72%; P = 0.50) for the same three-study comparison. Neither shows a significant difference.

06
3 months

Function change (ΔVISA-A)

Victorian Institute of Sports Assessment–Achilles (VISA-A) WMD points in change score

WMD3.9CI 95% -1.4 to 9.19p = 0.15

ESWT versus sham ESWT

2 studies · 154 participants in this estimate · 37%

-2.7Equal results 010.5

Reported estimate and confidence interval.

No statistically significant pooled between-group difference was reported.

Analysis details and source

I²=37%; source-reported pooled change-score estimate.

07
6 months

Function change (ΔVISA-A)

Victorian Institute of Sports Assessment–Achilles (VISA-A) WMD points in change score

WMD1.51CI 95% -4.13 to 7.14p = 0.60

ESWT versus sham ESWT

2 studies · 138 participants in this estimate · 0%

-5.5Equal results 08.5

Reported estimate and confidence interval.

No statistically significant pooled between-group difference was reported.

Analysis details and source

I²=0%; source-reported pooled change-score estimate.

Function change (ΔAOFAS)3 reported outcomes
08
1 month

Function change (ΔAOFAS)

American Orthopaedic Foot and Ankle Society (AOFAS) score WMD points in change score

WMD2.25CI 95% -0.6 to 5.11p = 0.12

ESWT versus sham ESWT

4 studies · 0%

-1.3Equal results 05.8

Reported estimate and confidence interval.

The source reports no significant difference. Table 4 prints the number of studies/patients in reversed or malformed order for AOFAS; participant count is therefore left null.

Analysis details and source

I²=0%; source-reported pooled change-score estimate.

09
3 months

Function change (ΔAOFAS)

American Orthopaedic Foot and Ankle Society (AOFAS) score WMD points in change score

WMD3.82CI 95% -5.02 to 12.65p = 0.40

ESWT versus sham ESWT

3 studies · 82%

-7.1Equal results 014.8

Reported estimate and confidence interval.

The source reports no significant difference. Table 4 prints the number of studies/patients in reversed or malformed order for AOFAS; participant count is therefore left null.

Analysis details and source

I²=82%; source-reported pooled change-score estimate.

10
6 months

Function change (ΔAOFAS)

American Orthopaedic Foot and Ankle Society (AOFAS) score WMD points in change score

WMD-0.08CI 95% -4.63 to 4.48p = 0.97

ESWT versus sham ESWT

2 studies · 0%

-5.7Equal results 05.6

Reported estimate and confidence interval.

The source reports no significant difference. Table 4 prints the number of studies/patients in reversed or malformed order for AOFAS; participant count is therefore left null.

Analysis details and source

I²=0%; source-reported pooled change-score estimate.

Study-reported adverse events1 reported outcome
13
During treatment/follow-up as reported in contributing RCTs

Participants with adverse events

Study-reported adverse events Odds ratio

OR2.89CI 95% 0.75 to 11.04p = 0.12

ESWT versus sham

5 studies · 318 participants in this estimate · 35%

0.5Equal results 115.2

Reported estimate and confidence interval. Logarithmic ratio scale.

Seven of 156 ESWT participants and two of 162 sham participants had mild adverse events; the pooled difference was not statistically significant.

Analysis details and source

Reported events were mild and required no specific intervention. Participant count 318 is directly represented by the source arm denominators 156 and 162.

VAS pain change by modality: rESWT5 reported outcomes
14
1 month

VAS pain change by modality: rESWT

VAS pain change weighted mean difference, score points

WMD-0.37CI 95% -0.89 to 0.14p = 0.15

rESWT versus sham/control ESWT

5 studies · 305 participants in this estimate · I²=0%

-1Equal results 00.3

Reported estimate and confidence interval.

Modality subgroup estimate: −0.37 (95% CI -0.89 to 0.14; p=0.15; I²=0%). This exploratory result does not establish a treatment-modality interaction.

Analysis details and source

Exploratory Table 4 subgroup. The source contribution count is transcribed as shown. The source comparison is against sham ESWT/control.

15
1 month

VAS pain change by modality: rESWT + fESWT

VAS pain change weighted mean difference, score points

WMD-0.45CI 95% -1.45 to 0.64p = 0.42

rESWT + fESWT versus sham/control ESWT

1 study · 43 participants in this estimate · I²=NA

-1.7Equal results 00.9

Reported estimate and confidence interval.

Modality subgroup estimate: −0.45 (95% CI -1.45 to 0.64; p=0.42; I²=NA). This exploratory result does not establish a treatment-modality interaction.

Analysis details and source

Exploratory Table 4 subgroup. The source contribution count is transcribed as shown. The source comparison is against sham ESWT/control.

16
3 months

VAS pain change by modality: rESWT

VAS pain change weighted mean difference, score points

WMD-0.24CI 95% -1.28 to 0.81p = 0.65

rESWT versus sham/control ESWT

I²=68%

-1.5Equal results 01.1

Reported estimate and confidence interval.

Modality subgroup estimate: −0.24 (95% CI -1.28 to 0.81; p=0.65; I²=68%). This exploratory result does not establish a treatment-modality interaction.

Analysis details and source

Exploratory Table 4 subgroup. The printed study/patient contribution cell is malformed; counts are left null. The source comparison is against sham ESWT/control.

17
3 months

VAS pain change by modality: fESWT

VAS pain change weighted mean difference, score points

WMD-1.57CI 95% -3.4 to 0.26p = 0.09

fESWT versus sham/control ESWT

1 study · 49 participants in this estimate · I²=NA

-3.8Equal results 00.7

Reported estimate and confidence interval.

Modality subgroup estimate: −1.57 (95% CI -3.4 to 0.26; p=0.09; I²=NA). This exploratory result does not establish a treatment-modality interaction.

Analysis details and source

Exploratory Table 4 subgroup. The source contribution count is transcribed as shown. The source comparison is against sham ESWT/control.

18
3 months

VAS pain change by modality: rESWT + fESWT

VAS pain change weighted mean difference, score points

WMD-1.15CI 95% -2.3 to 0.02p = 0.06

rESWT + fESWT versus sham/control ESWT

1 study · 43 participants in this estimate · I²=NA

-2.6Equal results 00.3

Reported estimate and confidence interval.

Modality subgroup estimate: −1.15 (95% CI -2.3 to 0.02; p=0.06; I²=NA). This exploratory result does not establish a treatment-modality interaction.

Analysis details and source

Exploratory Table 4 subgroup. The source contribution count is transcribed as shown. The source comparison is against sham ESWT/control.

VISA-A function change by modality: rESWT4 reported outcomes
19
1 month

VISA-A function change by modality: rESWT

VISA-A function change weighted mean difference, scale points

WMD0.22CI 95% -11.54 to 11.97p = 0.97

rESWT versus sham/control ESWT

2 studies · 177 participants in this estimate · I²=80%

-14.4Equal results 014.8

Reported estimate and confidence interval.

Modality subgroup estimate: 0.22 (95% CI -11.54 to 11.97; p=0.97; I²=80%). This exploratory result does not establish a treatment-modality interaction.

Analysis details and source

Exploratory Table 4 subgroup. The source contribution count is transcribed as shown. The source comparison is against sham ESWT/control.

20
1 month

VISA-A function change by modality: fESWT

VISA-A function change weighted mean difference, scale points

WMD6.37CI 95% -1.22 to 10.26p = 0.12

fESWT versus sham/control ESWT

1 study · 42 participants in this estimate · I²=NA

-2.6Equal results 011.6

Reported estimate and confidence interval.

Modality subgroup estimate: 6.37 (95% CI -1.22 to 10.26; p=0.12; I²=NA). This exploratory result does not establish a treatment-modality interaction.

Analysis details and source

Exploratory Table 4 subgroup. The source contribution count is transcribed as shown. The source comparison is against sham ESWT/control. As printed (Table 4, fESWT row; also Table 5, Mixed row): the estimate 6.37 is not at the centre of its printed 95% CI (−1.22 to 10.26; centre 4.52), so one of these printed numbers is probably a misprint.

21
6 months

VISA-A function change by modality: rESWT

VISA-A function change weighted mean difference, scale points

WMD-2.4CI 95% -12.26 to 7.46p = 0.63

rESWT versus sham/control ESWT

1 study · 96 participants in this estimate · I²=NA

-14.6Equal results 09.8

Reported estimate and confidence interval.

Modality subgroup estimate: −2.40 (95% CI -12.26 to 7.46; p=0.63; I²=NA). This exploratory result does not establish a treatment-modality interaction.

Analysis details and source

Exploratory Table 4 subgroup. The source contribution count is transcribed as shown. The source comparison is against sham ESWT/control.

22
6 months

VISA-A function change by modality: fESWT

VISA-A function change weighted mean difference, scale points

WMD3.4CI 95% -3.46 to 10.26p = 0.33

fESWT versus sham/control ESWT

1 study · 42 participants in this estimate · I²=NA

-5.1Equal results 011.9

Reported estimate and confidence interval.

Modality subgroup estimate: 3.40 (95% CI -3.46 to 10.26; p=0.33; I²=NA). This exploratory result does not establish a treatment-modality interaction.

Analysis details and source

Exploratory Table 4 subgroup. The source contribution count is transcribed as shown. The source comparison is against sham ESWT/control.

AOFAS function change by modality: rESWT7 reported outcomes
23
1 month

AOFAS function change by modality: rESWT

AOFAS function change weighted mean difference, scale points

WMD1.99CI 95% -3.48 to 7.46p = 0.48

rESWT versus sham/control ESWT

I²=50%

-4.8Equal results 08.8

Reported estimate and confidence interval.

Modality subgroup estimate: 1.99 (95% CI -3.48 to 7.46; p=0.48; I²=50%). This exploratory result does not establish a treatment-modality interaction.

Analysis details and source

Exploratory Table 4 subgroup. The printed study/patient contribution cell is malformed; counts are left null. The source comparison is against sham ESWT/control.

24
1 month

AOFAS function change by modality: fESWT

AOFAS function change weighted mean difference, scale points

WMD3.2CI 95% -2.27 to 8.67p = 0.25

fESWT versus sham/control ESWT

I²=NA

-3.6Equal results 010

Reported estimate and confidence interval.

Modality subgroup estimate: 3.20 (95% CI -2.27 to 8.67; p=0.25; I²=NA). This exploratory result does not establish a treatment-modality interaction.

Analysis details and source

Exploratory Table 4 subgroup. The printed study/patient contribution cell is malformed; counts are left null. The source comparison is against sham ESWT/control.

25
1 month

AOFAS function change by modality: rESWT + fESWT

AOFAS function change weighted mean difference, scale points

WMD2.3CI 95% -4.52 to 9.12p = 0.51

rESWT + fESWT versus sham/control ESWT

I²=NA

-6.2Equal results 010.8

Reported estimate and confidence interval.

Modality subgroup estimate: 2.30 (95% CI -4.52 to 9.12; p=0.51; I²=NA). This exploratory result does not establish a treatment-modality interaction.

Analysis details and source

Exploratory Table 4 subgroup. The printed study/patient contribution cell is malformed; counts are left null. The source comparison is against sham ESWT/control.

26
3 months

AOFAS function change by modality: rESWT

AOFAS function change weighted mean difference, scale points

WMD3.34CI 95% -11.46 to 18.14p = 0.66

rESWT versus sham/control ESWT

I²=90%

-15Equal results 021.7

Reported estimate and confidence interval.

Modality subgroup estimate: 3.34 (95% CI -11.46 to 18.14; p=0.66; I²=90%). This exploratory result does not establish a treatment-modality interaction.

Analysis details and source

Exploratory Table 4 subgroup. The printed study/patient contribution cell is malformed; counts are left null. The source comparison is against sham ESWT/control.

27
3 months

AOFAS function change by modality: rESWT + fESWT

AOFAS function change weighted mean difference, scale points

WMD4.99CI 95% -1.84 to 11.82p = 0.15

rESWT + fESWT versus sham/control ESWT

I²=NA

-3.5Equal results 013.5

Reported estimate and confidence interval.

Modality subgroup estimate: 4.99 (95% CI -1.84 to 11.82; p=0.15; I²=NA). This exploratory result does not establish a treatment-modality interaction.

Analysis details and source

Exploratory Table 4 subgroup. The printed study/patient contribution cell is malformed; counts are left null. The source comparison is against sham ESWT/control.

28
6 months

AOFAS function change by modality: rESWT

AOFAS function change weighted mean difference, scale points

WMD-1.7CI 95% -8 to 4.6p = 0.60

rESWT versus sham/control ESWT

I²=NA

-9.5Equal results 06.1

Reported estimate and confidence interval.

Modality subgroup estimate: −1.70 (95% CI -8 to 4.6; p=0.60; I²=NA). This exploratory result does not establish a treatment-modality interaction.

Analysis details and source

Exploratory Table 4 subgroup. The printed study/patient contribution cell is malformed; counts are left null. The source comparison is against sham ESWT/control.

29
6 months

AOFAS function change by modality: fESWT

AOFAS function change weighted mean difference, scale points

WMD1.7CI 95% -4.89 to 8.29p = 0.61

fESWT versus sham/control ESWT

I²=NA

-6.5Equal results 09.9

Reported estimate and confidence interval.

Modality subgroup estimate: 1.70 (95% CI -4.89 to 8.29; p=0.61; I²=NA). This exploratory result does not establish a treatment-modality interaction.

Analysis details and source

Exploratory Table 4 subgroup. The printed study/patient contribution cell is malformed; counts are left null. The source comparison is against sham ESWT/control.

Adverse events by modality: rESWT3 reported outcomes
30
During follow-up as reported

Adverse events by modality: rESWT

Adverse events odds ratio

OR2.06CI 95% 0.09 to 46.09p = 0.65

rESWT versus sham/control ESWT

I²=61%

0Equal results 197.4

Reported estimate and confidence interval. Logarithmic ratio scale.

Modality subgroup estimate: 2.06 (95% CI 0.09 to 46.09; p=0.65; I²=61%). This exploratory result does not establish a treatment-modality interaction.

Analysis details and source

Exploratory Table 4 subgroup. The printed study/patient contribution cell is malformed; counts are left null. The source comparison is against sham ESWT/control.

31
During follow-up as reported

Adverse events by modality: fESWT

Adverse events odds ratio

OR6.71CI 95% 0.31 to 147.37p = 0.23

fESWT versus sham/control ESWT

I²=NA

0.1Equal results 1308.8

Reported estimate and confidence interval. Logarithmic ratio scale.

Modality subgroup estimate: 6.71 (95% CI 0.31 to 147.37; p=0.23; I²=NA). This exploratory result does not establish a treatment-modality interaction.

Analysis details and source

Exploratory Table 4 subgroup. The printed study/patient contribution cell is malformed; counts are left null. The source comparison is against sham ESWT/control.

32
During follow-up as reported

Adverse events by modality: rESWT + fESWT

Adverse events odds ratio

Table 4 reports the radial-plus-focused ESWT adverse-event subgroup as not estimable (43 participants, one study).

Analysis details and source

The source marks the estimate and interval as not estimable; no comparative effect is inferred.

VAS in diagnosis tendinopathy: insertional16 reported outcomes
33
1 month

VAS in diagnosis tendinopathy: insertional

VAS weighted mean difference, VAS points

WMD-0.2CI 95% -0.82 to 0.41p = 0.52

ESWT versus sham; subgroup: insertional

3 studies · 208 participants in this estimate · I²=16%

-1Equal results 00.6

Reported estimate and confidence interval.

VAS diagnosis subgroup at 1 month: -0.2 (95% CI -0.82 to 0.41; p=.52; I²=16%).

Analysis details and source

Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.

34
1 month

VAS in diagnosis tendinopathy: non-insertional

VAS weighted mean difference, VAS points

WMD-0.9CI 95% -2.36 to 0.56p = 0.23

ESWT versus sham; subgroup: non-insertional

1 study · 50 participants in this estimate · I²=NA

-2.7Equal results 00.9

Reported estimate and confidence interval.

VAS diagnosis subgroup at 1 month: -0.9 (95% CI -2.36 to 0.56; p=.23; I²=NA).

Analysis details and source

Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.

35
1 month

VAS in diagnosis tendinopathy: mixed

VAS weighted mean difference, VAS points

WMD-0.56CI 95% -1.38 to 0.26p = 0.18

ESWT versus sham; subgroup: mixed

2 studies · 90 participants in this estimate · I²=0%

-1.6Equal results 00.5

Reported estimate and confidence interval.

VAS diagnosis subgroup at 1 month: -0.56 (95% CI -1.38 to 0.26; p=.18; I²=0%).

Analysis details and source

Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.

36
3 month

VAS in diagnosis tendinopathy: insertional

VAS weighted mean difference, VAS points

WMD0.35CI 95% -0.31 to 1p = 0.30

ESWT versus sham; subgroup: insertional

I²=0%

-0.5Equal results 01.2

Reported estimate and confidence interval.

VAS diagnosis subgroup at 3 month: 0.35 (95% CI -0.31 to 1; p=.30; I²=0%). The source prints contribution cell “186 (3)”; study and participant counts are not assigned because the cell is malformed.

Analysis details and source

Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.

37
3 month

VAS in diagnosis tendinopathy: mixed

VAS weighted mean difference, VAS points

WMD-1.37CI 95% -2.11 to 0.63p = 0.08

ESWT versus sham; subgroup: mixed

I²=0%

-2.4Equal results 01

Reported estimate and confidence interval.

VAS diagnosis subgroup at 3 month: -1.37 (95% CI -2.11 to 0.63; p=.08; I²=0%). The source prints contribution cell “137 (3)”; study and participant counts are not assigned because the cell is malformed.

Analysis details and source

Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null. As printed in Table 5: the estimate −1.37 is not at the centre of its printed 95% CI (−2.11 to 0.63; centre −0.74), so one of these printed numbers is probably a misprint.

38
6 month

VAS in diagnosis tendinopathy: insertional

VAS weighted mean difference, VAS points

WMD0.14CI 95% -0.71 to 1p = 0.74

ESWT versus sham; subgroup: insertional

2 studies · 127 participants in this estimate · I²=0%

-0.9Equal results 01.2

Reported estimate and confidence interval.

VAS diagnosis subgroup at 6 month: 0.14 (95% CI -0.71 to 1; p=.74; I²=0%).

Analysis details and source

Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.

39
>6 months

VAS in diagnosis tendinopathy: non-insertional

VAS weighted mean difference, VAS points

WMD-0.5CI 95% -2.02 to 1.02p = 0.52

ESWT versus sham; subgroup: non-insertional

1 study · 50 participants in this estimate · I²=NA

-2.4Equal results 01.4

Reported estimate and confidence interval.

VAS diagnosis subgroup at >6 months: -0.5 (95% CI -2.02 to 1.02; p=.52; I²=NA).

Analysis details and source

Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.

40
>6 months

VAS in diagnosis tendinopathy: mixed

VAS weighted mean difference, VAS points

WMD-0.77CI 95% -2.61 to 1.07p = 0.41

ESWT versus sham; subgroup: mixed

1 study · 43 participants in this estimate · I²=NA

-3.1Equal results 01.5

Reported estimate and confidence interval.

VAS diagnosis subgroup at >6 months: -0.77 (95% CI -2.61 to 1.07; p=.41; I²=NA).

Analysis details and source

Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.

54
1 month

VAS in symptom duration tendinopathy: <12 months

VAS weighted mean difference, VAS points

WMD-0.76CI 95% -1.42 to -0.09p = 0.03

ESWT versus sham; subgroup: <12 months

4 studies · 173 participants in this estimate · I²=0%

-1.6Equal results 00.2

Reported estimate and confidence interval.

VAS symptom-duration subgroup at 1 month: -0.76 (95% CI -1.42 to -0.09; p=.03; I²=0%).

Analysis details and source

Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.

55
1 month

VAS in symptom duration tendinopathy: ≥12 months

VAS weighted mean difference, VAS points

WMD-0.03CI 95% -0.68 to 0.62p = 0.93

ESWT versus sham; subgroup: ≥12 months

2 studies · 177 participants in this estimate · I²=0%

-0.8Equal results 00.8

Reported estimate and confidence interval.

VAS symptom-duration subgroup at 1 month: -0.03 (95% CI -0.68 to 0.62; p=.93; I²=0%).

Analysis details and source

Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.

56
3 month

VAS in symptom duration tendinopathy: <12 months

VAS weighted mean difference, VAS points

WMD-1.23CI 95% -1.97 to -0.5p = 0.001

ESWT versus sham; subgroup: <12 months

3 studies · 119 participants in this estimate · I²=0%

-2.2Equal results 00.2

Reported estimate and confidence interval.

VAS symptom-duration subgroup at 3 month: -1.23 (95% CI -1.97 to -0.5; p=.001; I²=0%).

Analysis details and source

Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.

57
3 month

VAS in symptom duration tendinopathy: ≥12 months

VAS weighted mean difference, VAS points

WMD0.09CI 95% -0.95 to 1.12p = 0.87

ESWT versus sham; subgroup: ≥12 months

3 studies · 204 participants in this estimate · I²=55%

-1.2Equal results 01.4

Reported estimate and confidence interval.

VAS symptom-duration subgroup at 3 month: 0.09 (95% CI -0.95 to 1.12; p=.87; I²=55%).

Analysis details and source

Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.

58
6 month

VAS in symptom duration tendinopathy: <12 months

VAS weighted mean difference, VAS points

WMD0CI 95% -1.92 to 1.92p = 1.00

ESWT versus sham; subgroup: <12 months

1 study · 31 participants in this estimate · I²=NA

-2.4Equal results 02.4

Reported estimate and confidence interval.

VAS symptom-duration subgroup at 6 month: 0 (95% CI -1.92 to 1.92; p=1.00; I²=NA).

Analysis details and source

Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.

59
6 month

VAS in symptom duration tendinopathy: ≥12 months

VAS weighted mean difference, VAS points

WMD0.18CI 95% -0.77 to 1.13p = 0.71

ESWT versus sham; subgroup: ≥12 months

1 study · 96 participants in this estimate · I²=NA

-1Equal results 01.4

Reported estimate and confidence interval.

VAS symptom-duration subgroup at 6 month: 0.18 (95% CI -0.77 to 1.13; p=.71; I²=NA).

Analysis details and source

Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.

60
>6 months

VAS in symptom duration tendinopathy: <12 months

VAS weighted mean difference, VAS points

WMD-0.5CI 95% -2.02 to 1.02p = 0.52

ESWT versus sham; subgroup: <12 months

1 study · 50 participants in this estimate · I²=NA

-2.4Equal results 01.4

Reported estimate and confidence interval.

VAS symptom-duration subgroup at >6 months: -0.5 (95% CI -2.02 to 1.02; p=.52; I²=NA).

Analysis details and source

Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.

61
>6 months

VAS in symptom duration tendinopathy: ≥12 months

VAS weighted mean difference, VAS points

WMD-0.77CI 95% -2.61 to 1.07p = 0.41

ESWT versus sham; subgroup: ≥12 months

1 study · 43 participants in this estimate · I²=NA

-3.1Equal results 01.5

Reported estimate and confidence interval.

VAS symptom-duration subgroup at >6 months: -0.77 (95% CI -2.61 to 1.07; p=.41; I²=NA).

Analysis details and source

Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.

VISA-A in diagnosis tendinopathy: insertional8 reported outcomes
41
1 month

VISA-A in diagnosis tendinopathy: insertional

VISA-A weighted mean difference, score points

WMD0.22CI 95% -11.54 to 11.97p = 0.97

ESWT versus sham; subgroup: insertional

2 studies · 177 participants in this estimate · I²=80%

-14.4Equal results 014.8

Reported estimate and confidence interval.

VISA-A diagnosis subgroup at 1 month: 0.22 (95% CI -11.54 to 11.97; p=.97; I²=80%).

Analysis details and source

Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.

42
1 month

VISA-A in diagnosis tendinopathy: mixed

VISA-A weighted mean difference, score points

WMD6.37CI 95% -1.22 to 10.26p = 0.12

ESWT versus sham; subgroup: mixed

1 study · 42 participants in this estimate · I²=NA

-2.6Equal results 011.6

Reported estimate and confidence interval.

VISA-A diagnosis subgroup at 1 month: 6.37 (95% CI -1.22 to 10.26; p=.12; I²=NA).

Analysis details and source

Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. As printed (Table 5, Mixed row; also Table 4, fESWT row): the estimate 6.37 is not at the centre of its printed 95% CI (−1.22 to 10.26; centre 4.52), so one of these printed numbers is probably a misprint.

43
3 month

VISA-A in diagnosis tendinopathy: insertional

VISA-A weighted mean difference, score points

WMD3.9CI 95% -1.4 to 9.19p = 0.15

ESWT versus sham; subgroup: insertional

2 studies · 154 participants in this estimate · I²=37%

-2.7Equal results 010.5

Reported estimate and confidence interval.

VISA-A diagnosis subgroup at 3 month: 3.9 (95% CI -1.4 to 9.19; p=.15; I²=37%).

Analysis details and source

Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.

44
6 month

VISA-A in diagnosis tendinopathy: insertional

VISA-A weighted mean difference, score points

WMD-2.4CI 95% -12.26 to 7.46p = 0.63

ESWT versus sham; subgroup: insertional

1 study · 96 participants in this estimate · I²=NA

-14.6Equal results 09.8

Reported estimate and confidence interval.

VISA-A diagnosis subgroup at 6 month: -2.4 (95% CI -12.26 to 7.46; p=.63; I²=NA).

Analysis details and source

Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.

45
6 month

VISA-A in diagnosis tendinopathy: mixed

VISA-A weighted mean difference, score points

WMD3.4CI 95% -3.46 to 10.26p = 0.33

ESWT versus sham; subgroup: mixed

1 study · 42 participants in this estimate · I²=NA

-5.1Equal results 011.9

Reported estimate and confidence interval.

VISA-A diagnosis subgroup at 6 month: 3.4 (95% CI -3.46 to 10.26; p=.33; I²=NA).

Analysis details and source

Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.

62
1 month

VISA-A in symptom duration tendinopathy: ≥12 months

VISA-A weighted mean difference, score points

WMD3.26CI 95% -0.98 to 7.49p = 0.13

ESWT versus sham; subgroup: ≥12 months

3 studies · 219 participants in this estimate · I²=72%

-2Equal results 08.5

Reported estimate and confidence interval.

VISA-A symptom-duration subgroup at 1 month: 3.26 (95% CI -0.98 to 7.49; p=.13; I²=72%).

Analysis details and source

Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. This row repeats the overall three-study estimate; the Results text reports WMD 2.79 (95% CI −5.27 to 10.86; P = 0.50) for that comparison instead.

63
3 month

VISA-A in symptom duration tendinopathy: ≥12 months

VISA-A weighted mean difference, score points

WMD3.9CI 95% -1.4 to 9.19p = 0.15

ESWT versus sham; subgroup: ≥12 months

2 studies · 154 participants in this estimate · I²=37%

-2.7Equal results 010.5

Reported estimate and confidence interval.

VISA-A symptom-duration subgroup at 3 month: 3.9 (95% CI -1.4 to 9.19; p=.15; I²=37%).

Analysis details and source

Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.

64
6 month

VISA-A in symptom duration tendinopathy: ≥12 months

VISA-A weighted mean difference, score points

WMD1.51CI 95% -4.13 to 7.14p = 0.60

ESWT versus sham; subgroup: ≥12 months

2 studies · 138 participants in this estimate · I²=0%

-5.5Equal results 08.5

Reported estimate and confidence interval.

VISA-A symptom-duration subgroup at 6 month: 1.51 (95% CI -4.13 to 7.14; p=.60; I²=0%).

Analysis details and source

Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.

AOFAS in diagnosis tendinopathy: insertional11 reported outcomes
46
1 month

AOFAS in diagnosis tendinopathy: insertional

AOFAS weighted mean difference, score points

WMD-0.6CI 95% -5.65 to 4.45p = 0.82

ESWT versus sham; subgroup: insertional

I²=NA

-6.9Equal results 05.7

Reported estimate and confidence interval.

AOFAS diagnosis subgroup at 1 month: -0.6 (95% CI -5.65 to 4.45; p=.82; I²=NA). The source prints contribution cell “108 (1)”; study and participant counts are not assigned because the cell is malformed.

Analysis details and source

Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.

47
1 month

AOFAS in diagnosis tendinopathy: mixed

AOFAS weighted mean difference, score points

WMD3.49CI 95% -0.27 to 7.05p = 0.07

ESWT versus sham; subgroup: mixed

I²=0%

-1.1Equal results 07.9

Reported estimate and confidence interval.

AOFAS diagnosis subgroup at 1 month: 3.49 (95% CI -0.27 to 7.05; p=.07; I²=0%). The source prints contribution cell “132 (3)”; study and participant counts are not assigned because the cell is malformed.

Analysis details and source

Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.

48
3 month

AOFAS in diagnosis tendinopathy: insertional

AOFAS weighted mean difference, score points

WMD-4.1CI 95% -10.08 to 1.88p = 0.18

ESWT versus sham; subgroup: insertional

I²=NA

-11.5Equal results 03.3

Reported estimate and confidence interval.

AOFAS diagnosis subgroup at 3 month: -4.1 (95% CI -10.08 to 1.88; p=.18; I²=NA). The source prints contribution cell “82 (1)”; study and participant counts are not assigned because the cell is malformed.

Analysis details and source

Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.

49
3 month

AOFAS in diagnosis tendinopathy: mixed

AOFAS weighted mean difference, score points

WMD3.96CI 95% -2.14 to 7.85p = 0.08

ESWT versus sham; subgroup: mixed

I²=31%

-3.3Equal results 09

Reported estimate and confidence interval.

AOFAS diagnosis subgroup at 3 month: 3.96 (95% CI -2.14 to 7.85; p=.08; I²=31%). The source prints contribution cell “88 (2)”; study and participant counts are not assigned because the cell is malformed.

Analysis details and source

Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null. As printed (Table 5, Mixed row; also Table 6, <12 months row): the estimate 3.96 is not at the centre of its printed 95% CI (−2.14 to 7.85; centre about 2.86), so one of these printed numbers is probably a misprint.

50
6 month

AOFAS in diagnosis tendinopathy: insertional

AOFAS weighted mean difference, score points

WMD-1.7CI 95% -8 to 4.6p = 0.60

ESWT versus sham; subgroup: insertional

I²=NA

-9.5Equal results 06.1

Reported estimate and confidence interval.

AOFAS diagnosis subgroup at 6 month: -1.7 (95% CI -8 to 4.6; p=.60; I²=NA). The source prints contribution cell “96 (1)”; study and participant counts are not assigned because the cell is malformed.

Analysis details and source

Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.

51
6 month

AOFAS in diagnosis tendinopathy: mixed

AOFAS weighted mean difference, score points

WMD1.7CI 95% -4.89 to 8.29p = 0.61

ESWT versus sham; subgroup: mixed

I²=NA

-6.5Equal results 09.9

Reported estimate and confidence interval.

AOFAS diagnosis subgroup at 6 month: 1.7 (95% CI -4.89 to 8.29; p=.61; I²=NA). The source prints contribution cell “42 (1)”; study and participant counts are not assigned because the cell is malformed.

Analysis details and source

Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.

65
1 month

AOFAS in symptom duration tendinopathy: <12 months

AOFAS weighted mean difference, score points

WMD3.85CI 95% -0.61 to 8.3p = 0.09

ESWT versus sham; subgroup: <12 months

I²=0%

-1.7Equal results 09.4

Reported estimate and confidence interval.

AOFAS symptom-duration subgroup at 1 month: 3.85 (95% CI -0.61 to 8.3; p=.09; I²=0%). The source prints contribution cell “90 (2)”; study and participant counts are not assigned because the cell is malformed.

Analysis details and source

Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.

66
1 month

AOFAS in symptom duration tendinopathy: ≥12 months

AOFAS weighted mean difference, score points

WMD1.15CI 95% -2.56 to 4.86p = 0.54

ESWT versus sham; subgroup: ≥12 months

I²=0%

-3.5Equal results 05.8

Reported estimate and confidence interval.

AOFAS symptom-duration subgroup at 1 month: 1.15 (95% CI -2.56 to 4.86; p=.54; I²=0%). The source prints contribution cell “150 (2)”; study and participant counts are not assigned because the cell is malformed.

Analysis details and source

Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.

67
3 month

AOFAS in symptom duration tendinopathy: <12 months

AOFAS weighted mean difference, score points

WMD3.96CI 95% -2.14 to 7.85p = 0.08

ESWT versus sham; subgroup: <12 months

I²=31%

-3.3Equal results 09

Reported estimate and confidence interval.

AOFAS symptom-duration subgroup at 3 month: 3.96 (95% CI -2.14 to 7.85; p=.08; I²=31%). The source prints contribution cell “88 (2)”; study and participant counts are not assigned because the cell is malformed.

Analysis details and source

Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null. As printed (Table 6, <12 months row; also Table 5, Mixed row): the estimate 3.96 is not at the centre of its printed 95% CI (−2.14 to 7.85; centre about 2.86), so one of these printed numbers is probably a misprint.

68
3 month

AOFAS in symptom duration tendinopathy: ≥12 months

AOFAS weighted mean difference, score points

WMD-4.1CI 95% -10.08 to 1.88p = 0.18

ESWT versus sham; subgroup: ≥12 months

I²=NA

-11.5Equal results 03.3

Reported estimate and confidence interval.

AOFAS symptom-duration subgroup at 3 month: -4.1 (95% CI -10.08 to 1.88; p=.18; I²=NA). The source prints contribution cell “82 (1)”; study and participant counts are not assigned because the cell is malformed.

Analysis details and source

Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.

69
6 month

AOFAS in symptom duration tendinopathy: ≥12 months

AOFAS weighted mean difference, score points

WMD-0.08CI 95% -4.63 to 4.48p = 0.97

ESWT versus sham; subgroup: ≥12 months

I²=0%

-5.7Equal results 05.6

Reported estimate and confidence interval.

AOFAS symptom-duration subgroup at 6 month: -0.08 (95% CI -4.63 to 4.48; p=.97; I²=0%). The source prints contribution cell “138 (2)”; study and participant counts are not assigned because the cell is malformed.

Analysis details and source

Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.

adverse-events in diagnosis tendinopathy: insertional4 reported outcomes
52
During follow-up as reported

adverse-events in diagnosis tendinopathy: insertional

adverse-events odds ratio

OR2.06CI 95% 0.09 to 46.09p = 0.65

ESWT versus sham; subgroup: insertional

I²=61%

0Equal results 197.4

Reported estimate and confidence interval. Logarithmic ratio scale.

adverse-events diagnosis subgroup during follow-up as reported: 2.06 (95% CI 0.09 to 46.09; p=.65; I²=61%). The source prints contribution cell “226 (3)”; study and participant counts are not assigned because the cell is malformed.

Analysis details and source

Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.

53
During follow-up as reported

adverse-events in diagnosis tendinopathy: mixed

adverse-events odds ratio

OR6.71CI 95% 0.31 to 147.37p = 0.23

ESWT versus sham; subgroup: mixed

I²=NA

0.1Equal results 1308.8

Reported estimate and confidence interval. Logarithmic ratio scale.

adverse-events diagnosis subgroup during follow-up as reported: 6.71 (95% CI 0.31 to 147.37; p=.23; I²=NA). The source prints contribution cell “92 (2)”; study and participant counts are not assigned because the cell is malformed.

Analysis details and source

Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.

70
During follow-up as reported

adverse-events in symptom duration tendinopathy: <12 months

adverse-events odds ratio

OR11.16CI 95% 0.55 to 227.6p = 0.12

ESWT versus sham; subgroup: <12 months

I²=NA

0.3Equal results 1469

Reported estimate and confidence interval. Logarithmic ratio scale.

adverse-events symptom-duration subgroup during follow-up as reported: 11.16 (95% CI 0.55 to 227.6; p=.12; I²=NA). The source prints contribution cell “74 (2)”; study and participant counts are not assigned because the cell is malformed.

Analysis details and source

Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.

71
During follow-up as reported

adverse-events in symptom duration tendinopathy: ≥12 months

adverse-events odds ratio

OR1.52CI 95% 0.12 to 19.73p = 0.75

ESWT versus sham; subgroup: ≥12 months

I²=42%

0.1Equal results 136.4

Reported estimate and confidence interval. Logarithmic ratio scale.

adverse-events symptom-duration subgroup during follow-up as reported: 1.52 (95% CI 0.12 to 19.73; p=.75; I²=42%). The source prints contribution cell “244 (3)”; study and participant counts are not assigned because the cell is malformed.

Analysis details and source

Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.

How treatment was delivered
ESWT modalities and dose range

Four studies radial, three focused, one combined; reported protocols used about 1,500–4,500 shocks/session over mostly three to four sessions. Intensities ranged 0.1–0.6 mJ/mm² or 1.5–5 bar as source-reported; do not convert between units.

Sham and co-interventions

Sham methods included zero energy, disconnected probes, air cavities or interposed material to attenuate waves while reproducing device cues. Seven studies matched exercise, stretching or education across arms; protocols varied.

HARMS & TOLERABILITY

Five RCTs reported mild adverse events: 7/156 ESWT participants (4.5%) versus 2/162 sham participants (1.2%). Events did not require specific medical intervention; pooled OR 2.89 (95% CI 0.75–11.04; p=.12), with no statistically significant difference.

LIMITS OF THE ANALYSIS

The review included only eight trials and outcome-level participant totals were modest. The authors rated primary findings low to moderate certainty; modality and disease-subtype subgroup analyses were constrained.

Raw XML Tables 4–6 contain malformed or apparently reversed study/patient count cells for some AOFAS and subgroup rows. Those participant counts are not used unless clearly reported in prose or unambiguous cells. The linked supplementary raw data were unavailable.

All significant symptom-duration results are exploratory subgroup findings, including one below the stated MCID. They do not override null overall pooled comparisons.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • The review included only eight trials and outcome-level participant totals were modest. The authors rated primary findings low to moderate certainty; modality and disease-subtype subgroup analyses were constrained.
  • Raw XML Tables 4–6 contain malformed or apparently reversed study/patient count cells for some AOFAS and subgroup rows. Those participant counts are not used unless clearly reported in prose or unambiguous cells. The linked supplementary raw data were unavailable.
  • All significant symptom-duration results are exploratory subgroup findings, including one below the stated MCID. They do not override null overall pooled comparisons.
Research review

Source-linked critical reading

Systematic review with meta-analysis

Reading depthMaterial consulted
Technical source record

Complete full-text XML read with all six raw tables and figure captions inspected; results and each section of discussion/conclusions read. Three linked supplements were not part of retrieved XML.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Design and evidence base

PRISMA systematic review and meta-analysis of randomized sham-controlled trials. Searches covered four databases through February 20, 2025; eight RCTs were included. Primary outcomes were changes in VAS, VISA-A and AOFAS.

Participants

Eight trials included 458 participants with chronic Achilles tendinopathy (symptoms ≥3 months), including insertional, non-insertional and mixed presentations. The review reports study-level totals; outcome-specific pooled samples vary by timepoint.

Intervention protocols

Four studies used radial ESWT, three focused ESWT and one combined modalities. Protocols varied in device, intensity, shocks and schedules; most delivered three or four sessions. Seven trials also provided balanced exercise/education co-interventions.

Comparator

ESWT was compared with sham designed to mimic the procedure while attenuating or eliminating pressure waves. Co-interventions were generally matched within each trial.

Outcomes

Across follow-ups, pooled mean differences in change scores were nonsignificant for VAS, VISA-A and AOFAS. At 1, 3, 6 and >6 months, VAS WMDs were −0.39, −0.56, 0.14 and −0.61; all CIs included no difference. VISA-A at 1, 3 and 6 months and AOFAS at 1, 3 and 6 months were also nonsignificant.

Between-group findings

Primary pooled estimates did not show ESWT superiority over sham. Exploratory subgroup analyses found lower VAS change scores for symptoms <12 months at 1 month (WMD −0.76, 95% CI −1.42 to −0.09) and 3 months (−1.23, −1.97 to −0.50); authors flag these as hypothesis-generating, and only the 3-month estimate exceeded the stated 1.1-point VAS MCID.

Harms

Five studies reported mild events not requiring specific treatment. Events occurred in 7/156 ESWT participants (4.5%) and 2/162 sham participants (1.2%); pooled OR 2.89 (95% CI 0.75–11.04; p=.12), not statistically significant.

Limitations

Eight trials and modest outcome-specific samples limited precision. Protocols, devices, co-interventions and populations varied; secondary reporting includes malformed Table 4/5 cells where study and participant counts appear reversed or inconsistent. Publication bias was not formally assessed because fewer than ten studies contributed. Subgroups are exploratory.

Applicability

The sham comparison estimates the specific incremental effect of ESWT beyond procedure context and shared co-care. Overall findings do not establish added pain or functional benefit. The early-symptom subgroup signal is uncertain and cannot guide treatment alone.

What stronger evidence needs

Future sham-controlled trials should standardize diagnosis, ESWT parameters and matched loading programs, report complete outcome-level denominators and confidence intervals, monitor adverse events, and prospectively power prespecified symptom-duration analyses.

THE ORIGINAL SOURCE

Read the original article.

Extracorporeal shockwave therapy versus sham extracorporeal shockwave therapy for chronic Achilles tendinopathy: a meta-analysis of randomized controlled trials.

Ni T, Zhao Y, Pang L, Fu W. · PeerJ · 2026

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →